MCF7A AKT1 [MCF7-AKT1] cell line

This cell line is also resistant to Geneticin which may be included in the culture to maintain the expression plasmid

Contributors

Inventor Institute
Lambert Dorssers Erasmus University Medical Center (Erasmus MC)
SKU: 154636
Product description: Breast cancer is widely and effectively treated with endocrine treatment. However, in many disease cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotypeSeven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in MCF7A human breast cancer cells. This cell line is part of a panel of 4 cell lines (Cat No 154636-154638, 154643) which have been transfected with these genes, plus the parental (Cat No 154546)These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
Alternate name: AKT Serine/Threonine Kinase 1; Protein Kinase B; PKB; RAC
Production details: Full length AKT1 cDNA was introduced in the estrogen-dependent MCF7A cell line by transfection with lipofectamine
Parental cell line: MCF7A
Disease: Cancer
Cat. #: 154636
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer;Drug development
Organism: Human
Tissue: Breast
Model: Cancer Model
Cancer Types In Detail: Estrogen dependent;Mammary adenocarcinoma
Format: Frozen
Storage conditions: Liquid Nitrogen
Shipping conditions: Dry ice
Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS)
Mycoplasma free: Yes
Biosafety level: 1
References:

van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015.

Images

View Gallery

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.